FQ
JNCE

First Quadrant’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

First Quadrant’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-37,800
Closed -$257K – 563
2021
Q2 		$257K Buy
+37,800
New +$314K 0.03% 317

Other funds holding JNCE

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

First Quadrant's JNCE Position: Q3 2021 in Review

First Quadrant sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2021, closing a stake of 37,800 shares — an estimated $257K sold.

First Quadrant first reported a position in JNCE in Q2 2021 and held it in 1 quarter. The position peaked at $257K in Q2 2021. 115 funds tracked by Wall St. Rank hold JNCE as of Q3 2021.

  • First Quadrant reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • First Quadrant sold 37,800 Jounce Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $257K.
  • First Quadrant first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • First Quadrant's Jounce Therapeutics, Inc. Common Stock position peaked at $257K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2021.

Based on First Quadrant's 13F filing for Q3 2021, filed 26 Oct 2021.